{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T20:38:58Z","timestamp":1783456738398,"version":"3.55.0"},"reference-count":58,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Defibrotide (DF) is a mixture of porcine-derived single-stranded phosphodiester oligonucleotides (9-80-mer; average, 50-mer) that has been successfully used to treat severe hepatic veno-occlusive disease (sVOD) with multiorgan failure (MOF) in patients who have received cytotoxic chemotherapy in preparation for bone marrow transplantation. However, its mechanism of action is unknown. Herein, we show that DF and phosphodiester oligonucleotides can bind to heparin-binding proteins (eg, basic fibroblast growth factor [bFGF] but not vascular endothelial growth factor [VEGF] 165) with low nanomolar affinity. This binding occurred in a length- and concentration-dependent manner. DF can mobilize proangiogenic factors such as bFGF from their depot or storage sites on bovine corneal endothelial matrix. However, these molecules do not interfere with high-affinity binding of bFGF to FGFR1 IIIc but can replace heparin as a required cofactor for binding and hence cellular mitogenesis. DF also protects bFGF against digestion by trypsin and chymotrypsin and from air oxidation. In addition, DF binds to collagen I with low nanomolar affinity and can promote human microvascular endothelial cell-1 (HMEC-1) cell mitogenesis and tubular morphogenesis in three-dimensional collagen I gels. Thus, our data suggest that DF may provide a stimulus to the sinusoidal endothelium of a liver that has suffered a severe angiotoxic event, thus helping to ameliorate the clinical sVOD\/MOF syndrome.<\/jats:p>","DOI":"10.1182\/blood-2008-04-149682","type":"journal-article","created":{"date-parts":[[2008,8,19]],"date-time":"2008-08-19T00:50:00Z","timestamp":1219107000000},"page":"4343-4352","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":52,"title":["Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease"],"prefix":"10.1182","volume":"112","author":[{"given":"Luba","family":"Benimetskaya","sequence":"first","affiliation":[{"name":"Albert Einstein-Montefiore Cancer Center, Montefiore Medical Center, Depertment of Oncology, Bronx, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijian","family":"Wu","sequence":"additional","affiliation":[{"name":"Albert Einstein-Montefiore Cancer Center, Montefiore Medical Center, Depertment of Oncology, Bronx, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatoliy M.","family":"Voskresenskiy","sequence":"additional","affiliation":[{"name":"Albert Einstein-Montefiore Cancer Center, Montefiore Medical Center, Depertment of Oncology, Bronx, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinara","family":"Echart","sequence":"additional","affiliation":[{"name":"Gentium S.p.A., Villa Guardia, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Feng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Albert Einstein-Montefiore Cancer Center, Montefiore Medical Center, Depertment of Oncology, Bronx, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joongho","family":"Shin","sequence":"additional","affiliation":[{"name":"Albert Einstein-Montefiore Cancer Center, Montefiore Medical Center, Depertment of Oncology, Bronx, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Iacobelli","sequence":"additional","affiliation":[{"name":"Gentium S.p.A., Villa Guardia, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanyalakshmi","family":"Ayyanar","sequence":"additional","affiliation":[{"name":"Albert Einstein-Montefiore Cancer Center, Montefiore Medical Center, Depertment of Oncology, Bronx, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"Stein","sequence":"additional","affiliation":[{"name":"Albert Einstein-Montefiore Cancer Center, Montefiore Medical Center, Depertment of Oncology, Bronx, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111718165285200_B1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/oli.2006.16.105","article-title":"Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with life-saving activity in severe hepatic veno-occlusive disease: Clinical outcomes and potential mechanisms of action.","volume":"16","author":"Kornblum","year":"2006","journal-title":"Oligonucleotides"},{"key":"2019111718165285200_B2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/00003495-199345020-00007","article-title":"A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders.","volume":"45","author":"Palmer","year":"1993","journal-title":"Drugs"},{"key":"2019111718165285200_B3","first-page":"737","article-title":"Treatment of severe veno-occlusive disease with Defibrotide: Compassionate use results in response without significant toxicity in a high-risk population.","volume":"92","author":"Richardson","year":"1998","journal-title":"Blood"},{"key":"2019111718165285200_B4","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1046\/j.1365-2141.2000.02475.x","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease: Results of the European compassionate-use study.","volume":"111","author":"Chopra","year":"2000","journal-title":"Br J Haematol"},{"key":"2019111718165285200_B5","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2002-04-1216","article-title":"Multi-institutional use of Defibrotide in 88 patients after stem cell transplant with severe veno-occlusive disease and multi-system organ failure: Response without significant toxicity in a high-risk population and factors predictive of outcome.","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"2019111718165285200_B6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2002-23204","article-title":"Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (veno-occlusive disease).","volume":"22","author":"DeLeve","year":"2002","journal-title":"Semin Liver Dis"},{"key":"2019111718165285200_B7","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","article-title":"The syndrome of hepatic veno-occlusive disease after marrow transplantation.","volume":"85","author":"Bearman","year":"1995","journal-title":"Blood"},{"key":"2019111718165285200_B8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients.","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"key":"2019111718165285200_B9","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1200\/JCO.1993.11.9.1729","article-title":"Venoocclusive disease of the liver: development of a model predicting fatal outcome after marrow transplantation.","volume":"11","author":"Bearman","year":"1993","journal-title":"J Clin Oncol"},{"key":"2019111718165285200_B10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000046590","article-title":"Hepatic veno-occlusive disease following hematopoietic stem cell transplantation.","volume":"106","author":"Richardson","year":"2001","journal-title":"Acta Haematol"},{"key":"2019111718165285200_B11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1345\/aph.10220","article-title":"Prevention and treatment of veno-occlusive disease.","volume":"35","author":"Pegram","year":"2001","journal-title":"Ann Pharmacother"},{"key":"2019111718165285200_B12","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/sj.leu.2403004","article-title":"Defibrotide reduces activity and increases fibrinolytic properties of endothelial cells.","volume":"17","author":"Falanga","year":"2003","journal-title":"Leukemia"},{"key":"2019111718165285200_B13","first-page":"A256","article-title":"Tissue factor pathway inhibitor (TFPI) release induced by defibrotide and heparins.","author":"Cella","journal-title":"Thromb Haemo Suppl"},{"key":"2019111718165285200_B14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF00609244","article-title":"Acute effects of Defibrotide, an experimntal anti-thrombotic agent, on fibrinolysis and blood prostanoids in man.","volume":"35","author":"Coccheri","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"2019111718165285200_B15","doi-asserted-by":"crossref","first-page":"G1045","DOI":"10.1152\/ajpgi.00526.2002","article-title":"Embolization by sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome.","volume":"284","author":"DeLeve","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2019111718165285200_B16","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1074\/jbc.270.6.2620","article-title":"Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix.","volume":"270","author":"Guvakova","year":"1995","journal-title":"J Biol Chem"},{"key":"2019111718165285200_B17","doi-asserted-by":"crossref","first-page":"18818","DOI":"10.1016\/S0021-9258(17)46701-9","article-title":"Oligodeoxynucleotides interact with recombinant CD4 at multiple sites.","volume":"268","author":"Yakubov","year":"1993","journal-title":"J Biol Chem"},{"key":"2019111718165285200_B18","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant and the concentration of inhibitor which causes 50% inhibition.","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"2019111718165285200_B19","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1021\/bi00122a027","article-title":"Importance of size and sulfation of heparin in release of basic fibroblast growth factor from the vascular endothelium and extracellular matrix.","volume":"31","author":"Ishai-Michaeli","year":"1992","journal-title":"Biochemistry"},{"key":"2019111718165285200_B20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1006\/mvre.1998.2122","article-title":"A novel, quantitative model for study of endothelial cell migration and sprout formation within three-dimensional collagen matrices.","volume":"57","author":"Vernon","year":"1999","journal-title":"Microvasc Res"},{"key":"2019111718165285200_B21","first-page":"36","article-title":"Image processing with ImageJ.","volume":"11","author":"Abramoff","year":"2004","journal-title":"Biophotonics Int"},{"key":"2019111718165285200_B22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0076-6879(94)45013-7","article-title":"Regulation by heparan sulfate in fibroblast growth factor signaling.","volume":"245","author":"Rapraeger","year":"1994","journal-title":"Methods Enzymol"},{"key":"2019111718165285200_B23","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1021\/bi00360a001","article-title":"Identification of the fibroblast growth factor receptor of Swiss 3T3 cells and mouse skeletal fibroblasts.","volume":"25","author":"Olwin","year":"1986","journal-title":"Biochemistry"},{"key":"2019111718165285200_B24","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1128\/MCB.12.12.5600","article-title":"Identification of a cysteine-rich receptor for fibroblast growth factors.","volume":"12","author":"Burrus","year":"1992","journal-title":"Mol Cell Biol"},{"key":"2019111718165285200_B25","first-page":"393","article-title":"A heparin-binding angiogenic protein-basic fibroblast growth factor is stored within basement membrane.","volume":"130","author":"Folkman","year":"1988","journal-title":"Am J Pathol"},{"key":"2019111718165285200_B26","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1083\/jcb.107.2.753","article-title":"Metabolism of receptor-bound and matrix-bound basic fibroblast growth factor by bovine capillary endothelial cells.","volume":"107","author":"Moscatelli","year":"1988","journal-title":"J Cell Biol"},{"key":"2019111718165285200_B27","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1074\/mcp.R400008-MCP200","article-title":"Polyanions and the proteome.","volume":"3","author":"Jones","year":"2004","journal-title":"Mol Cell Proteomics"},{"key":"2019111718165285200_B28","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1073\/pnas.84.8.2292","article-title":"Endothelial cell-derived basic fibroblast growth factor: Synthesis and deposition into subendothelial extracellular matrix.","volume":"84","author":"Vlodavsky","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111718165285200_B29","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1021\/bi00430a047","article-title":"Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules.","volume":"28","author":"Bashkin","year":"1989","journal-title":"Biochemistry"},{"key":"2019111718165285200_B30","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/0006-291X(87)90292-0","article-title":"Fibroblast growth factors are present in the extracellular matrix produced by endothelial cells in vitro: Implications for a role of heparinase-like enzymes in the neovascular response.","volume":"142","author":"Baird","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"2019111718165285200_B31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1677\/erc.0.0070165","article-title":"Fibroblast growth factors, their receptors and signaling.","volume":"7","author":"Powers","year":"2000","journal-title":"Endocr Relat Cancer"},{"key":"2019111718165285200_B32","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1172\/JCI119319","article-title":"Modulation of fibroblast growth factor-2 receptor binding, dimerization signaling and angiogenic activity by a synthetic heparin-mimicking polyanionic compound.","volume":"99","author":"Miao","year":"1997","journal-title":"J Clin Invest"},{"key":"2019111718165285200_B33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1128\/MCB.12.1.240","article-title":"Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells.","volume":"12","author":"Ornitz","year":"1992","journal-title":"Mol Cell Biol"},{"key":"2019111718165285200_B34","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/0092-8674(91)90512-W","article-title":"Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor.","volume":"64","author":"Yayon","year":"1991","journal-title":"Cell"},{"key":"2019111718165285200_B35","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1200\/JCO.2006.06.0483","article-title":"Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group.","volume":"24","author":"Bedikian","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111718165285200_B36","doi-asserted-by":"crossref","first-page":"C371","DOI":"10.1152\/ajpcell.00193.2002","article-title":"Fibroblast growth factor 2 promotes microvessel formation from mouse embryonic aorta.","volume":"284","author":"Akimoto","year":"2003","journal-title":"Am J Physiol Cell Physiol"},{"key":"2019111718165285200_B37","first-page":"26","article-title":"Biological roles of fibroblast growth factor-2.","volume":"18","author":"Bikfalvi","year":"1997","journal-title":"Endocr Rev"},{"key":"2019111718165285200_B38","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0065-230X(08)60305-X","article-title":"The FGF family of growth factors and oncogenes.","volume":"59","author":"Basilico","year":"1992","journal-title":"Adv Cancer Res"},{"key":"2019111718165285200_B39","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1083\/jcb.141.7.1659","article-title":"Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: An autocrine mechanism contributing to angiogenesis.","volume":"141","author":"Seghezzi","year":"1998","journal-title":"J Cell Biol"},{"key":"2019111718165285200_B40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/labinvest.3780212","article-title":"Fibroblast growth factor 2 activation of stromal cell vascular endothelial growth factor expression and angiogenesis.","volume":"81","author":"Claffey","year":"2001","journal-title":"Lab Investig"},{"key":"2019111718165285200_B41","first-page":"96","article-title":"A fucosylated chondroitin sulfate from echinoderm modulates in vitro fibroblast growth factor 2-dependent angiogenesis.","volume":"1","author":"Tapon-Bretaudi\u00e8re","year":"2002","journal-title":"Mol Cancer Res"},{"key":"2019111718165285200_B42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1096\/fj.03-0948com","article-title":"Matrix-specific activation of Src and Rho initiates capillary morphogenesis of endothelial cells.","volume":"18","author":"Liu","year":"2004","journal-title":"FASEB J"},{"key":"2019111718165285200_B43","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1478-3231.2004.0914.x","article-title":"Hepatocyte survival depends on \u03b21-integrin-mediated attachment of hepatocytes to hepatic extracellular matrix.","volume":"24","author":"Pinkse","year":"2004","journal-title":"Liver Int"},{"key":"2019111718165285200_B44","first-page":"69","article-title":"A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides.","volume":"1489","author":"Levin","year":"1999","journal-title":"Biochem Biophys Acta"},{"key":"2019111718165285200_B45","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0171-9335(98)80094-0","article-title":"Modulation of human endothelial cell proliferation and migration by fucoidan and heparin.","volume":"77","author":"Giraux","year":"1998","journal-title":"Eur J Cell Biol"},{"key":"2019111718165285200_B46","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/blood.V89.6.2184","article-title":"Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation.","volume":"89","author":"Salat","year":"1997","journal-title":"Blood"},{"key":"2019111718165285200_B47","first-page":"883","article-title":"Candidate genes for the hypoxic tumor phenotype.","volume":"60","author":"Koong","year":"2000","journal-title":"Cancer Res"},{"key":"2019111718165285200_B48","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1055\/s-0037-1613573","article-title":"Regulation of the hypoxia-dependent plasminogen activator inhibitor I expression by MAP kinases.","volume":"89","author":"Kietzmann","year":"2003","journal-title":"Thromb Haemost"},{"key":"2019111718165285200_B49","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0962-8924(94)90124-4","article-title":"The structural basis of integrin-ligand interactions.","volume":"4","author":"K\u00fchn","year":"1994","journal-title":"Trends Cell Biol"},{"key":"2019111718165285200_B50","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1083\/jcb.111.5.2159","article-title":"Human smooth muscle VLA-1 integrin: Purification, substrate specificity, localization in aorta, and expression during development.","volume":"111","author":"Belkin","year":"1990","journal-title":"J Cell Biol"},{"key":"2019111718165285200_B51","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1083\/jcb.111.2.709","article-title":"Molecular cloning of the rat integrin alpha-1 subunit: A receptor for laminin and collagen.","volume":"111","author":"Ignatius","year":"1990","journal-title":"J Cell Biol"},{"key":"2019111718165285200_B52","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.1021\/bi00479a028","article-title":"Alpha 1 beta 1 integrin heterodimer functions as a dual laminin\/collagen receptor in neural cells.","volume":"29","author":"Tawil","year":"1990","journal-title":"Biochemistry"},{"key":"2019111718165285200_B53","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nm0497-414","article-title":"Mac-1 (CD11b\/CD18) is a cell surface oligodeoxynucleotide binding protein.","volume":"3","author":"Benimetskaya","year":"1997","journal-title":"Nature Med"},{"key":"2019111718165285200_B54","doi-asserted-by":"crossref","first-page":"8848","DOI":"10.1074\/jbc.M313204200","article-title":"Connective tissue growth factor (CCN2) induces adhesion of rat activated hepatic stellate cells by binding of its C-terminal domain to integrin \u03b1v\u03b23 and heparan sulfate proteoglycan.","volume":"279","author":"Gao","year":"2004","journal-title":"J Biol Chem"},{"key":"2019111718165285200_B55","doi-asserted-by":"crossref","first-page":"24953","DOI":"10.1074\/jbc.M003040200","article-title":"Adhesion of human skin fibroblasts to cyr61 is mediated through integrin \u03b16\u03b21 and cell surface heparan sulfate proteoglycans.","volume":"275","author":"Chen","year":"2000","journal-title":"J Biol Chem"},{"key":"2019111718165285200_B56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1074\/jbc.275.1.35","article-title":"The collagen-binding A-domains of integrins \u03b11\u03b21 and \u03b12\u03b21 recognize the same specific amino acid sequence, GFOGER, in native (triple-helical) collagens.","volume":"275","author":"Knight","year":"2000","journal-title":"J Biol Chem"},{"key":"2019111718165285200_B57","first-page":"e1","article-title":"An endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo.","volume":"6","author":"Koehl","year":"2007","journal-title":"Cancer Biol Therap"},{"key":"2019111718165285200_B58","first-page":"108","article-title":"Defibrotide, an oraly bioavailable modulator of myeloma tumor-microenvironment interactions: molecular sequelae and clinical implications [abstract].","author":"Mitsiades","year":"2006","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/10\/4343\/1483041\/zh802208004343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/10\/4343\/1483041\/zh802208004343.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T03:47:16Z","timestamp":1631677636000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/112\/10\/4343\/24640\/Angiogenesis-alteration-by-defibrotide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,15]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,11,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-04-149682","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,15]]}}}